The effect of antiviral therapy on the clinical outcomes of chronic hepatitis B
10.3760/cma.j.issn.1003-9279.2017.06.020
- VernacularTitle: 抗病毒治疗对慢性乙型病毒性肝炎临床结局的影响
- Author:
Xingyue WANG
1
;
Lu ZHANG
;
Minghui LI
Author Information
1. Liver Center of Beijing Ditan Hospital, Capital Medical University, Beijing100015, China
- Publication Type:Review
- Keywords:
Chronic hepatitis B;
Interferon;
Nucleoside analog;
Clinical outcomes
- From:
Chinese Journal of Experimental and Clinical Virology
2017;31(6):570-575
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis B (CHB) is a chronic inflammation of liver which infected with the hepatitis B virus (HBV). The chronic inflammation of liver will lead to cirrhosis, complications of liver decompensation from cirrhosis, hepatocellular carcinoma (HCC) and even death.There are two kinds of drugs are available for the treatment: interferon(IFN)which including IFN-αand pegylated IFN, and nucleoside analog(NAs) which including lamivudine, adefovir dipivoxil, entecavir, telbivudine and Tenofovir disoproxil fumarate.We will describe the mechanisms of the CHB, INF and NAs to state the effect on the clinical outcome(cirrhosis, complications from cirrhosis, hepatocellular carcinoma and death) of the therapy of antiviral therapies.
